Scarica l'app Stockscreener
14.44
0.35%
0.05
Dopo l'orario di chiusura:
14.44
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché RDY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$14.39
Aprire:
$14.29
Volume 24 ore:
1.09M
Relative Volume:
0.56
Capitalizzazione di mercato:
$12.05B
Reddito:
$3.85B
Utile/perdita netta:
$667.93M
Rapporto P/E:
21.98
EPS:
0.657
Flusso di cassa netto:
$142.30M
1 W Prestazione:
+7.76%
1M Prestazione:
+7.44%
6M Prestazione:
+1.91%
1 anno Prestazione:
+4.18%
Intervallo 1D:
$14.27
$14.46
Intervallo di 1 settimana:
$13.40
$14.46
Portata 52W:
$12.26
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Confronta RDY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
14.44 | 11.15B | 3.85B | 667.93M | 142.30M | 0.657 |
|
HLN
Haleon Plc Adr
|
10.80 | 48.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
163.04 | 70.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.85 | 3.54M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.11 | 45.20B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.94 | 19.42B | 16.54B | -1.64B | 749.00M | -1.45 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Nomura | Buy → Neutral |
| 2024-01-11 | Downgrade | Jefferies | Buy → Underperform |
| 2023-08-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-05-18 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-30 | Iniziato | JP Morgan | Underweight |
| 2022-11-14 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Ripresa | BofA Securities | Neutral |
| 2021-07-27 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-09-18 | Aggiornamento | Investec | Sell → Hold |
| 2020-01-28 | Downgrade | CLSA | Buy → Outperform |
| 2020-01-27 | Downgrade | CLSA | Buy → Outperform |
| 2020-01-09 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-11-04 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Aggiornamento | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2019-06-20 | Iniziato | Deutsche Bank | Hold |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Aggiornamento | CLSA | Outperform → Buy |
| 2019-01-17 | Downgrade | Citigroup | Neutral → Sell |
| 2017-09-21 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Aggiornamento | CLSA | Underperform → Outperform |
| 2017-07-28 | Downgrade | CLSA | Underperform → Sell |
| 2016-07-27 | Downgrade | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Downgrade | Jefferies | Hold → Underperform |
| 2016-02-10 | Aggiornamento | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Dr Reddys Laboratories Ltd Adr Borsa (RDY) Ultime notizie
Indian ADRs Surge in US Markets as Wall Street soars after US-China trade talks - Moneycontrol
Asian Equities Climb Despite Weekly Losses - Finimize
Dr. Reddy’s Laboratories Grants Stock Options to Employees in May 2025 - TipRanks
Insider’s View: Deciphering Six Flags Entertainment Corp (FUN)’s Financial Health Through Ratios - DWinneX
Balance Sheet Breakdown: Astrazeneca plc ADR (AZN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Ratio Examination: Dr. Reddy’s Laboratories Ltd. ADR (RDY)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Financial Analysis: Spotify Technology S.A (SPOT)’s Ratios Unveil Key Insights - DWinneX
5 Indian ADRs crash up to 14% amid rising India-Pakistan military conflict - Trade Brains
Indian Markets Set for Bloody Friday as Gift Nifty Signals Sharp Gap-Down Open Amid Escalating India-Pak Tensions - outlookbusiness.com
Indian ADRs slump as India-Pakistan conflict sees escalation - Moneycontrol
Validea's Top Health Care Stocks Based On Peter Lynch5/5/2025 - Nasdaq
Asian ADRs See Mixed Results Despite Weekly Gains - Finimize
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Dr. Reddy’s Looks Well Positioned for Long-Term Growth, Aided by Acquisitions and Partnerships - Morningstar
Investing in Dr. Reddy’s Laboratories Ltd. ADR (RDY): What You Must Know - knoxdaily.com
LLY Stock Quote Price and Forecast - CNN
NVO Stock Quote Price and Forecast - CNN
Zacks Industry Outlook Dr. Reddy's, Sandoz And Teva Pharmaceuticals - Barchart.com
Asian ADRs Climb, Showcasing North And South Asia Performances - Finimize
PDD Holdings Stock Delivers Phenomenal 5.82% Surge to $95.77 on April 14 – Bullish Momentum Lifts Chinese Tech - Hindustan Herald
3 Generic Drug Stocks To Watch Amid Trade War Jitters & Inflation Woes - Barchart.com
Stocks to buy in 2025: Uno Minda, Dr Reddy’s Laboratories among top picks that could give 10-50% return - The Economic Times
Asian ADRs Shine As Zai Lab And CNFinance Lead The Gains - Finimize
Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by Massachusetts Financial Services Co. MA - MarketBeat
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - TradingView
Mixed Performance For Asian Stocks Traded On US Markets - Finimize
Vanguard Group Inc. Purchases 3,911,404 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) - Defense World
Asian Equities Traded in the US as American Depositary Receipts Tumble in Thursday Trading - TradingView
Pinpoint Asset Management Ltd Acquires 473,000 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Dr Reddy's Slapped Rs 2,395 Cr Income Tax Notice, Pharma Giant Denies Allegations - Medical Dialogues
Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Monday Trading - TradingView
Stocks to watch, April 7: IT, pharma, metals, oil-sensitive stocks, Nykaa, Dr Reddy's, Delhivery, Trent Ltd, and more - Upstox
Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority - Moneycontrol
TCS, Dr Reddy's Labs among 6 large and mid-cap stocks that hit 52-week lows on Friday - The Economic Times
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView
Sensex Today | Stock Market Highlights: Sensex falls 322 points, Nifty slips 82 points as IT drags - CNBC TV18
Asian Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading - TradingView
Generics Industry: India Celebrates Pharmaceutical Tariffs Exemption but Uncertainty Remains High - Morningstar
US Tariffs on Pharma: Zydus, Dr Reddy’s at highest risk, says Jefferies; Check impact on other Indian pharma stocks - Mint
Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by GQG Partners LLC - MarketBeat
American Healthcare REIT Inc (AHR) Stock: A Year of Decreases and Increases - The InvestChronicle
Asian Equities Traded in the US as ADRs Rise in Tuesday Trading - MSN
Top Indian ADRs by Market Cap: HDFC Bank, ICICI Bank & More - INDmoney
Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Dr Reddys Laboratories Ltd Adr Azioni (RDY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):